fda warning letters glp-1 compounders october 2025 issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's September crackdown on misleading Why the FDA Issued 30

The dominant categories are cell-culture studies in dermal fibroblasts and keratinocytes (collagen biochemistry, gene-expression observations, signal-transduction effects), copper-chemistry studies (chelation stability, antioxidant chemistry), and small-animal wound-repair models

They give you the conversion math but do not tell you that certain concentration-dose combinations are nearly impossible to measure accurately with standard equipment

If you have obesity-related conditionssuch as type 2 diabetes, hypertension, or sleep apneastarting now with an approved injectable GLP-1 may make sense

While it might be beneficial in acute stress responses, chronic elevation of long-chain acylcarnitines is linked to conditions like insulin resistance, type 2 diabetes, and cardiovascular diseases

GrayCSHildrethAJSandercockPAO'ConnellJEJohnstonDECartlidgeNEet al